Editor's Note: Story has been updated to correct the date of Biogen's merger with Idec Pharmaceuticals.
Biogen Idec, a biotechnology company with 1,300 employees in the Triangle, said Thursday it plans to add 100 positions here to meet surging demand.
The new positions will include manufacturing associates who run manufacturing processes, quality assurance technicians and engineers. The company is filling positions at its biologics facility in Morrisville and its small dose facility in Durham.
Cambridge, Mass.-based Biogen, which produces medicines to treat multiple sclerosis and hemophilia, said its revenue has increased by more than 50 percent in the past three years and more growth is expected this year. Revenue in 2014 was $9.7 billion, a 40 percent increase over 2013.
Driving the growth was the approval of three new products in 2014, including Alprolix and Eloctate for hemophilia and Plegridy for MS.
Biogen first built a manufacturing facility here in 1995; it 2003 the company merged with Idec Pharmaceuticals in a $6.8 billion deal.
Biogen produces seven therapies – five for MS and two for hemophilia. Six are made in the Triangle.